Healthcare entity
Every one of those 1 sits in a single category, market-trends. Triple-G Agonist is most often covered alongside Eli Lilly, which appears in 1 of these 1 story. Their average consequence score of 7 runs above the beat's 6 for that window.
Last mentioned: Feb 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Triple-G Agonist is most often covered alongside Eli Lilly, which appears in 1 of these 1 story. Their average consequence score of 7 runs above the beat's 6 for that window. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. Triple-G Agonist appears in 1 tracked Healthcare story from February 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Triple-G Agonist. Shared-story counts are live from our verified record — not editorial picks.
Regulatory Submissions
Expected window for the first triple-agonist drug applications to the FDA.
Novo Triple-G Phase 2
Novo Nordisk reports nearly 20% weight loss at 26 weeks.
Phase 3 Expansion
Anticipated start of Novo Nordisk's pivotal late-stage clinical program.
Lilly Retatrutide Phase 2
Eli Lilly releases data showing 17.5% weight loss at 24 weeks.
Novo Nordisk's midstage trial for its 'triple-G' agonist demonstrated nearly 20% weight loss in patients after 26 weeks, positioning it as a potent competitor to Eli Lilly’s retatrutide. While the efficacy data appears slightly superior to Lilly's midstage results, Novo remains behind in the clinical timeline, likely reaching the market second.
Source: Endpoints News · Endpoints News
Triple-G Agonist is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
